del17p对非裔美国人与白人多发性骨髓瘤患者生存影响无差异:VA研究
该VA队列研究纳入2243例有多发性骨髓瘤且del17p数据可用的患者,发现del17p总体患病率为8.83%,非裔美国人(5.56%)显著低于白人(10.52%,P<.001)。但无论年龄,del17p患者中非裔与白人生存无显著差异;无del17p的年轻非裔总生存仍优于年轻白人(7.75 vs 5.10年,P=.042)。
要点
- del17p在非裔美国人多发性骨髓瘤中患病率显著低于白人。
- del17p患者中非裔与白人生存无显著差异,提示该突变预后不良跨种族一致。
- 无del17p的年轻非裔总生存仍优于年轻白人,生存优势主要非由del17p解释。
核心结论
- 非裔美国人多发性骨髓瘤中del17p患病率低于白人,但del17p对生存的不良影响无种族差异。
- 年轻非裔相对年轻白人的生存优势主要归因于del17p以外的因素。
研究设计与样本
- 回顾性队列研究,基于VA系统2243例有多发性骨髓瘤且del17p数据可用的患者。
主要发现
- del17p总体患病率为8.83%,非裔为5.56%,白人为10.52%(P<.001)。
- 年轻非裔(<65岁)与年轻白人del17p患病率分别为4.34%与9.8%(P=.004)。
- del17p患者中非裔与白人无论年龄组生存均无显著差异。
- 无del17p的年轻非裔与年轻白人总生存分别为7.75年与5.10年(P=.042)。
临床怎么用
- del17p检测结果在不同种族中均应视为不良预后标志。
- 年轻非裔多发性骨髓瘤患者的生存优势不能仅用del17p缺失解释,需综合评估其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a heterogeneous disease that has an increased incidence in African Americans (AAs). We previously observed that, with equal access to health care, younger AA patients (age < 65 years) have superior overall survival (OS) compared with younger White patients. Because MM prognosis is influenced by 17p deletion (del17p), we investigated racial differences in its occurrence and impact in a large cohort of MM patients from the Veterans Affairs (VA) system. Among 2243 VA patients with MM for whom del17p data were available, del17p was present in 8.83% of all patients, with a significantly lower prevalence in AAs (5.56%) compared with Whites (10.52%; P < .001). The difference was even more pronounced among younger AAs (<65 years) vs younger Whites (4.34% vs 9.8%, respectively; P = .004). However, we did not observe any significant difference in survival between AA and White patients with del17p, regardless of age category, suggesting that del17p carries a poor prognosis across race and age. Interestingly, among patients without del17p, we still noted a significantly superior OS in younger AAs compared with younger Whites (7.75 vs 5.10 years; P = .042). Our study shows a lower incidence of del17p in AAs but suggests that the survival advantage for younger AAs is primarily due to factors other than del17p.
引用
- Fillmore NR, Cirstea D, Munjuluri A, et al. Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv. 2021. PMID: 34428278. doi:10.1182/bloodadvances.2020004001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。